Forbion

Forbion is a dedicated life sciences VC firm with offices in the Netherlands and Germany that works with entrepreneurs to build life sciences companies with technologies designed to transform patient’s lives. Forbion invests in life sciences companies that are active in the (bio-)pharma space. Forbion’s investment team has built an impressive performance track record since the late nineties with successful investments in over 50 companies. Forbion manages well over €1 billion across ten funds. Besides financial objectives, Forbion selects investments that will positively affect health and well-being of patients. Forbion also operates a joint venture with BGV, which manages three separate seed and early stage funds focused on Benelux.

Facts & Figures

Bedrijf Hoofdkantoor Website Telefoonnummer Actief in Managing Partner(s) Medewerkers Actieve fondsen Enterprise value portfoliobedrijven Aantal bedrijven in portfolio Aantal acquisities 2019 & 2020 Exits 2019 & 2020 Investeringsfocus Investeringstermijn Sectorfocus Average equity ticket Investments (op volgorde van laatst aangekochte) Forbion Gooimeer 2-35, 1411 DC Naarden www.forbion.com +31 (0)35 699 3000 Nederland, Duitsland & Singapore 3 26 Forbion Fund IV €10-500 miljoen 19

5 Life Sciences 10 jaar Biotech; Life sciences €10-35 miljoen Promedior, KaNDy, Infazome, Dyne (NASDAQ:DYN), Enterprise

Martien van Osch

Managing Partner martien.van.osch@forbion.com Martien van Osch is managing partner and splits his time between operational activities of the Firm and spearheading the medical device related activities at Forbion. He currently actively contributes to the boards of Mitralign and Autonomic Technologies.

Sander Slootweg

Managing Partner +31 (0)35 699 3015 sander.slootweg@forbion.com Sander Slootweg is managing partner and co-founded ABN AMRO Capital Life Sciences in 2000 and Forbion in 2006. At Forbion, he is responsible for Fundraising, Investor- and Public Relations. On the portfolio management side, he currently serves on the boards of Forbion’s portfolio companies NorthSea Therapeutics, Replimune, Inc., Xention Discovery and Oxyrane Ltd.

Geert-Jan Mulder

Managing Partner geertjan.mulder@forbion.com

Robbert van de Griendt

Head of Investor Relations & ESG +31 (0)35 699 3025 robbert.van.de.griendt@forbion.com

Marco Boorsma

General Partner +31 (0)35 699 3022 marco.boorsma@forbion.com

Dirk Kersten

General Partner +31 (0)35 699 3000 dirk.kersten@forbion.com

Holger Reithinger

General Partner +31 (0)35 699 3000 holger.reithinger@forbion.com Geert-Jan Mulder is managing partner and co-founded Forbion in 2006, holds a Medical Degree, has a background in clinical development and medical marketing. He hands-on supports portfolio companies in these matters. Geert-Jan serves on the board of several Forbion companies. Successful past investment include Acorda,

Insmed, bluebirdbio, PanGenetics and Exosome Dx. At Forbion, Robbert van de Griendt is responsible for Fundraising and Investor Relations. He also leads Forbion’s ESG and impact investing efforts. Before joining Forbion, he founded Accretion Capital Partners, advising asset managers structuring their products, raising funds for alternative asset classes, including Private Equity and Venture Capital, from Canadian and European institutions, family offices and accredited

investors. Marco Boorsma is general partner, has a background in molecular biology and biotechnology, and brings operational and business development experience from both small and large businesses. He is responsible for the deal flow process and currently serves on the Board of EnGene, Inflazome, Escalier, Milestone Pharma, and NorthSea

Therapeutics. Dirk Kersten is general partner at Forbion focusing on new investments. He is a physicist by training and previously worked at Gilde Healthcare Partners. He was a managing director at INKEF Capital responsible for all healthcare investment activities. Dirk led of investments in Europe and the US and was an board member at: Ascendis Pharma (ASND), Profibrix (acquired by MEDCO), Lanthio Pharma (acquired by Morphosys), Nightbalance (acquired by Philips), Audion Therapeutics, GTX and Vicentra (private).

Holger Reithinger is general partner and head of Forbion’s German Office. He started his career in Venture Capital in 1997 as an investment manager at Technologieholding VC. Holger has served on the Boards of numerous life sciences companies including Agendia, Santaris (sold to Roche 2014), Curetis (IPO 2015), Cellnovo Group (IPO 2015) and Rigontec (sold to MSD 2017). He holds board seats at Allecra Therapeutics, catalYm, Omeicos and Gotham.